Thrombin's Double Life: Procoagulant vs. Anticoagulant
Thrombin, which induces thrombus formation by forming a fibrin mesh, also plays an anticoagulant role within intact, undamaged blood vessels. Its anticoagulant function is mainly carried out through cooperation with thrombomodulin (TM), protein C, and protein S. When thrombin binds to platelet receptors (PAR-1, 4), it activates platelets and promotes coagulation. However, when it binds to thrombomodulin receptors on the endothelial cell membrane, its affinity for protein C increases dramatically, leading to anticoagulant activity.
After platelets aggregate to form a plug covering the damaged site, thrombin comes into contact with thrombomodulin upon reaching intact endothelial cells. Because thrombin has a higher affinity for thrombomodulin than for fibrin, it begins to bind with thrombomodulin instead, switching from a procoagulant to an anticoagulant role, thereby protecting the endothelium. Heparan sulfate on the surface of intact endothelial cells also binds thrombin to inhibit its activity.
Additionally, the thrombin-thrombomodulin complex activates the zymogen form of protein C by cleaving it. Activated protein C, in turn, deactivates coagulation factors FVa and FVIIIa, thus slowing or halting the amplification of coagulation. To function more efficiently, protein C must bind to protein S. The thrombin-thrombomodulin interaction functions like a natural anticoagulant pathway, preventing excessive fibrin clot formation caused by overactive thrombin. Note that both protein C and protein S are vitamin K-dependent.
Thrombin's dual behavior, often likened to that of a chameleon, is also related to sodium (Na⁺). Thrombin can exist in two forms: the Na⁺-bound fast form, which promotes coagulation, and the Na⁺-free slow form, which promotes anticoagulation. When Na⁺ binds to specific amino acid sequences in thrombin, its active site becomes more exposed, facilitating fibrinogen cleavage and increasing its affinity for factors V and VIII, thus accelerating coagulation. When thrombin performs its anticoagulant function, it is converted to Na+-free slow form. The fact that plasma Na⁺ concentration can influence blood coagulation highlights the involvement of various ions in this process.
Various Inhibitors and Suppression Mechanisms Across Coagulation Stages
Each stage of coagulation includes distinct inhibitors and regulatory mechanisms to prevent excessive clotting. These are also illustrated in diagrammatic form.
Fibrinolysis: Thrombus Degradation
The final stage of blood coagulation is fibrinolysis. Once the damaged blood vessel is healed following primary and secondary hemostasis, the clot that initially served its purpose must be appropriately removed to restore normal blood flow. This is akin to dismantling scaffolding after construction is complete. The thrombus is formed by a fibrin mesh that entraps numerous platelets, leukocytes, and red blood cells. To release these trapped components, the fibrin network must be cleaved. The enzyme responsible for specifically cleaving fibrin is plasmin.
Plasmin
The liver produces plasminogen for fibrin degradation. Plasminogen circulates in plasma as an inactive zymogen until activated by specific factors. To activate plasminogen into plasmin, it requires the action of either tissue-type plasminogen activator (tPA), which is secreted by endothelial cells and acts within the blood vessels, or urokinase-type plasminogen activator (uPA), which primarily functions outside the blood vessels, on cell surfaces or within the surrounding tissue environment.
To prevent premature or excessive clot breakdown, PAI-1 and α2-antiplasmin act as inhibitors. PAI-1 (Plasminogen Activator Inhibitor-1) inhibits tPA and uPA, preventing the conversion of plasminogen to plasmin, while α2-antiplasmin directly inhibits active plasmin, ensuring fibrin degradation does not proceed too quickly. A balanced interplay between activators and inhibitors ensures the timely breakdown of thrombi. These activators and inhibitors are also used therapeutically to treat bleeding disorders caused by excessive fibrinolysis or thrombotic cardiovascular diseases caused by insufficient clot resolution.
Biomarker of Thrombus Formation and Resolution: D-dimer
When the fibrin mesh is cleaved, the trapped platelets, leukocytes, and erythrocytes are released. most of them have been trapped for a long time and are damaged or already necrotic. Macrophages act as cleanup agents, engulfing and removing them via phagocytosis. Components like iron from red blood cells are recycled. Fibrin fibers are also broken down into small fragments called fibrin degradation products (FDPs). Among these, D-dimer is particularly important.
Previously, we illustrated how fibrinogen is converted into fibrin, which forms non-covalent fibrin polymers. These polymers are cross-linked by factor XIIIa to form a stable fibrin mesh. While plasmin can cleave both fibrinogen and fibrin, it cannot cleave the cross-linked regions of fibrin. When cross-linked fibrin is degraded, the resulting fragment containing two linked D domains is known as a D-dimer. Thus, the presence of D-dimer is clear evidence that cross-linked fibrin has undergone degradation, making it a "smoking gun" biomarker of fibrinolysis. D-dimer levels can be measured to assess the activity of the fibrinolytic process. Elevated D-dimer indicates that thrombus formation and subsequent degradation have occurred.
D-dimer Test
The D-dimer test measures D-dimer concentration in the blood to diagnose and monitor thrombotic conditions. Elevated D-dimer levels help identify potential thrombotic diseases like deep vein thrombosis (DVT) or pulmonary embolism (PE), often prompting further diagnostic testing. After surgery, D-dimer levels are monitored; persistently high levels may suggest thrombosis, necessitating medical intervention. Because D-dimer is a unique byproduct of fibrin degradation, it serves as a useful biomarker in various clinical monitoring contexts.
Additionally, as expected, the many fragments produced during fibrinolysis—such as FDPs, D-dimer, DNA fragments, and cell debris—may be recognized by immune cells as damage-associated molecular patterns (DAMPs). Pattern recognition receptors (PRRs) on immune cells like macrophages and dendritic cells can identify these fragments as antigens, potentially triggering an inflammatory response. Excessive immune reactions to these fragments could even lead to autoimmune responses.
[References]
